• Home
  • DeepCeutix
  • DeepC Biologics Agents: Biologic Formulation and CMC

DeepC Biologics Agents: Biologic Formulation and CMC

  • DeepC Biologics Agents: Biologic Formulation and CMC 1
  • DeepC Biologics Agents: Biologic Formulation and CMC 2
  • DeepC Biologics Agents: Biologic Formulation and CMC 3
Product Description

Specialist AI agents that do biologics formulation and CMC work across antibodies, ADCs, bispecifics, mRNA-LNP, AAV and cell therapy. Give DeepC a molecule, sequence or program and get decision-ready deliverables in minutes: biologic formulation strategies with excipient and buffer selection justified by approved precedent, CMC development frameworks, precedent landscapes of approved and pipeline biologics, and biologic freedom-to-operate analysis. Every recommendation is anchored to primary sources: approved product labels, EPARs and review reports, antibody structure and sequence databases, LNP formulation data and patents. Validated with leading pharmaceutical companies. We know your IP is everything. So is keeping it yours: single-tenant VPC, customer-managed encryption, 21 CFR Part 11-aligned audit log. Your data is never used to train our models. deepceutix.com

Read more Show less

DeepCeutix

  • Country/Region:
    United Kingdom
  • Founded:
    2025
  • On CPHI since:
    2026
  • Employees:
    1 - 24
Company types
Start-up
Primary activities
Technology
View company profile
Categories
more categories Show less
Specifications
  • Details
    Specifications
    • Specialist agents: Biologics Research, Biologics FTO, Biologics Formulation & CMC
    • Modalities: monoclonal antibodies, bispecifics, ADCs, mRNA-LNP, AAV gene therapy, cell therapy
    • Anchored to FDA Purple Book, EMA biosimilar and ATMP register, FDA OTAT, SAbDab and Thera-SAbDab, PLAbDab (sequence-similarity FTO), Open Targets, Cellosaurus, LNP Atlas, UniProt, PDB and AlphaFold
    • Reports follow ICH Q5A-E, Q6B, Q13 and Q14
    Application areas
    • High-concentration subcutaneous mAb formulation; buffer, surfactant and stabiliser selection
    • Biosimilar and originator precedent landscaping
    • ADC and bispecific CMC frameworks; LNP composition precedent; AAV and cell-therapy CMC
    • Biologic freedom-to-operate by sequence and keyword
  • Selling Points
    Convenience; Product Features; Product Performance; Quality Service;
    • CMC memos in the structure reviewers expect
    • Precedent from approved labels, EPARs and review reports
    • Sequence-aware freedom-to-operate
    • mAbs, bispecifics, ADCs, mRNA-LNP, AAV and cell therapy in one workspace
    • Live demos at CPHI Milan 2026, Hall 8, stand 8S72, 6 to 8 October
    • deepceutix.com
  • Supplied from
    United Kingdom
More specifications Fewer specifications
Sales Markets
Show more Show less

DeepCeutix

  • Country/Region:
    United Kingdom
  • Founded:
    2025
  • On CPHI since:
    2026
  • Employees:
    1 - 24
Company types
Start-up
Primary activities
Technology
View company profile

More Products from DeepCeutix (2)

  • DeepC Research Agents: AI Co-Scientists for Formulation Development

    Product DeepC Research Agents: AI Co-Scientists for Formulation Development

    Specialist AI agents that do formulation development work, end to end. Describe the problem in plain language; DeepC plans the work, routes it to the right specialists and returns decision-ready deliverables in minutes: complete development assessments, excipient selection justified against precedent and t...
  • DeepC Safety Agents: PDE, OEL, E&L and Nitrosamine Assessments

    Product DeepC Safety Agents: PDE, OEL, E&L and Nitrosamine Assessments

    Produce dossier-ready safety assessments in minutes. Specialist agents cover permitted daily exposure (PDE/ADE) monographs, occupational exposure limits (OEL), extractables and leachables risk assessments, nitrosamine risk evaluation and environmental risk assessment (ERA), each anchored to ICH, EMA, FDA a...